Multiple Sclerosis Research Group, Monash Immunology and Stem Cell Laboratories, Monash University, Clayton, Victoria, Australia.
Curr Stem Cell Res Ther. 2011 Mar;6(1):50-62. doi: 10.2174/157488811794480735.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that is characterised by an autoimmune attack on components of the myelin sheath and axons leading to neurological disability. Although long-approved current treatments for MS have so far only targeted immune components of the disease in a non-specific manner, the efficacy of these immunomodulatory treatments are limited given that they are only immunosuppressive and/ or immunoregulatory and do not prevent long-term disease progression. As such, there is a clear need for more effective therapies that are capable of targeting other aspects of the disease including neurodegeneration, demyelination and the underlying causes of the autoimmune state. Emerging data suggest that hematopoietic, mesenchymal and neural stem cells have the promise to restore self-tolerance, to provide in situ immunomodulation and neuroprotection as well as to promote regeneration. This review will summarise burgeoning experimental and clinical evidence supporting the application of these stem cell populations for the treatment of MS.
多发性硬化症(MS)是一种中枢神经系统的慢性炎症性疾病,其特征是自身免疫攻击髓鞘和轴突的成分,导致神经功能障碍。尽管目前已经批准的长期 MS 治疗方法迄今为止仅以非特异性方式靶向疾病的免疫成分,但由于这些免疫调节治疗仅具有免疫抑制和/或免疫调节作用,并且不能预防长期疾病进展,因此它们的疗效有限。因此,显然需要更有效的治疗方法,这些方法能够针对疾病的其他方面,包括神经退行性变、脱髓鞘和自身免疫状态的根本原因。新出现的数据表明,造血细胞、间充质细胞和神经干细胞有希望恢复自身耐受性,提供原位免疫调节和神经保护,并促进再生。本综述将总结支持这些干细胞群体用于治疗 MS 的新兴实验和临床证据。